Spatial Domains
Dominant neighborhood compartment and purity from Tier 1 domain summaries. Bulk files are centralized on the Download page.
101-150 of 2,070
Spatial Domains
Dominant neighborhood compartment and purity from Tier 1 domain summaries.
2,069 ready
| Sample | Organ | Disease state | Cells | Dominant compartment ?Largest Tier 1 spatial domain by sample fraction; this is a biological neighborhood label, not a row-count summary. | Domain share | Purity | Diversity |
|---|---|---|---|---|---|---|---|
| NSCLC_38242124__IMC__175_A7,10 | Lung | Primary cancer | 1,550 | Tumor/Malignant | 25.7% | 0.94 | 0.22 |
| NSCLC_38242124__IMC__175_A7,11 | Lung | Primary cancer | 3,752 | Tumor/Malignant | 32.5% | 0.98 | 0.12 |
| NSCLC_38242124__IMC__175_A7,12 | Lung | Primary cancer | 2,771 | Tumor/Malignant | 61.2% | 0.97 | 0.10 |
| NSCLC_38242124__IMC__175_A7,13 | Lung | Primary cancer | 1,886 | Tumor/Malignant | 51.4% | 0.98 | 0.09 |
| NSCLC_38242124__IMC__175_A7,14 | Lung | Primary cancer | 3,114 | Stromal | 38.2% | 0.79 | 0.52 |
| NSCLC_38242124__IMC__175_A7,15 | Lung | Primary cancer | 3,645 | Tumor/Malignant | 40.8% | 0.99 | 0.03 |
| NSCLC_38242124__IMC__175_A7,16 | Lung | Primary cancer | 3,722 | Tumor/Malignant | 55.6% | 0.98 | 0.12 |
| NSCLC_38242124__IMC__175_A7,17 | Lung | Primary cancer | 2,708 | Tumor/Malignant | 48.2% | 0.95 | 0.20 |
| NSCLC_38242124__IMC__175_A7,2 | Lung | Primary cancer | 5,150 | Stromal | 49.9% | 0.91 | 0.25 |
| NSCLC_38242124__IMC__175_A7,3 | Lung | Primary cancer | 875 | Tumor/Malignant | 49.7% | 0.96 | 0.18 |
| NSCLC_38242124__IMC__175_A7,4 | Lung | Primary cancer | 2,282 | Tumor/Malignant | 40.7% | 0.87 | 0.38 |
| NSCLC_38242124__IMC__175_A7,5 | Lung | Primary cancer | 3,115 | Tumor/Malignant | 87.2% | 0.99 | 0.03 |
| NSCLC_38242124__IMC__175_A7,6 | Lung | Primary cancer | 4,618 | Tumor/Malignant | 82.2% | 0.98 | 0.06 |
| NSCLC_38242124__IMC__175_A7,7 | Lung | Primary cancer | 3,440 | Tumor/Malignant | 27.0% | 0.54 | 0.91 |
| NSCLC_38242124__IMC__175_A7,8 | Lung | Primary cancer | 3,067 | Tumor/Malignant | 89.8% | 0.99 | 0.03 |
| NSCLC_38242124__IMC__175_A7,9 | Lung | Primary cancer | 3,130 | Tumor/Malignant | 36.1% | 0.48 | 0.74 |
| NSCLC_38242124__IMC__175_A8,1 | Lung | Primary cancer | 2,832 | Stromal | 28.3% | 0.77 | 0.57 |
| NSCLC_38242124__IMC__175_A8,10 | Lung | Primary cancer | 1,656 | Tumor/Malignant | 84.5% | 0.99 | 0.04 |
| NSCLC_38242124__IMC__175_A8,11 | Lung | Primary cancer | 2,245 | Tumor/Malignant | 61.9% | 0.99 | 0.10 |
| NSCLC_38242124__IMC__175_A8,12 | Lung | Primary cancer | 3,487 | Tumor/Malignant | 58.8% | 0.99 | 0.03 |
| NSCLC_38242124__IMC__175_A8,13 | Lung | Primary cancer | 2,819 | Tumor/Malignant | 38.2% | 0.74 | 0.56 |
| NSCLC_38242124__IMC__175_A8,14 | Lung | Primary cancer | 3,301 | Tumor/Malignant | 52.5% | 0.97 | 0.15 |
| NSCLC_38242124__IMC__175_A8,15 | Lung | Primary cancer | 3,533 | Tumor/Malignant | 45.7% | 0.94 | 0.22 |
| NSCLC_38242124__IMC__175_A8,16 | Lung | Primary cancer | 3,319 | Tumor/Malignant | 31.5% | 0.50 | 0.85 |
| NSCLC_38242124__IMC__175_A8,17 | Lung | Primary cancer | 2,542 | Tumor/Malignant | 33.8% | 0.77 | 0.59 |
| NSCLC_38242124__IMC__175_A8,2 | Lung | Primary cancer | 4,657 | Stromal | 56.6% | 0.93 | 0.19 |
| NSCLC_38242124__IMC__175_A8,3 | Lung | Primary cancer | 2,796 | Tumor/Malignant | 75.4% | 0.94 | 0.18 |
| NSCLC_38242124__IMC__175_A8,4 | Lung | Primary cancer | 2,444 | Tumor/Malignant | 29.8% | 0.84 | 0.49 |
| NSCLC_38242124__IMC__175_A8,5 | Lung | Primary cancer | 3,198 | Tumor/Malignant | 61.6% | 0.99 | 0.06 |
| NSCLC_38242124__IMC__175_A8,6 | Lung | Primary cancer | 5,540 | Tumor/Malignant | 79.0% | 0.99 | 0.04 |
| NSCLC_38242124__IMC__175_A8,7 | Lung | Primary cancer | 4,852 | Tumor/Malignant | 54.3% | 0.94 | 0.25 |
| NSCLC_38242124__IMC__175_A8,8 | Lung | Primary cancer | 2,748 | Tumor/Malignant | 57.5% | 0.99 | 0.04 |
| NSCLC_38242124__IMC__175_A8,9 | Lung | Primary cancer | 2,887 | Tumor/Malignant | 48.9% | 0.89 | 0.31 |
| NSCLC_38242124__IMC__175_B1,1 | Lung | Primary cancer | 2,779 | Tumor/Malignant | 53.0% | 0.93 | 0.25 |
| NSCLC_38242124__IMC__175_B1,10 | Lung | Primary cancer | 2,759 | Tumor/Malignant | 37.9% | 0.90 | 0.34 |
| NSCLC_38242124__IMC__175_B1,11 | Lung | Primary cancer | 3,245 | Tumor/Malignant | 35.3% | 0.89 | 0.41 |
| NSCLC_38242124__IMC__175_B1,12 | Lung | Primary cancer | 3,822 | Tumor/Malignant | 38.5% | 0.97 | 0.14 |
| NSCLC_38242124__IMC__175_B1,13 | Lung | Primary cancer | 2,076 | Tumor/Malignant | 29.9% | 0.95 | 0.24 |
| NSCLC_38242124__IMC__175_B1,14 | Lung | Primary cancer | 3,300 | Tumor/Malignant | 93.1% | 1.00 | 0.01 |
| NSCLC_38242124__IMC__175_B1,15 | Lung | Primary cancer | 2,725 | Tumor/Malignant | 74.1% | 0.97 | 0.11 |
| NSCLC_38242124__IMC__175_B1,16 | Lung | Primary cancer | 2,528 | Tumor/Malignant | 37.2% | 0.57 | 0.92 |
| NSCLC_38242124__IMC__175_B1,17 | Lung | Primary cancer | 1,429 | Stromal | 30.0% | 0.76 | 0.56 |
| NSCLC_38242124__IMC__175_B1,2 | Lung | Primary cancer | 2,305 | Tumor/Malignant | 56.0% | 0.90 | 0.29 |
| NSCLC_38242124__IMC__175_B1,3 | Lung | Primary cancer | 4,171 | Tumor/Malignant | 68.1% | 0.99 | 0.03 |
| NSCLC_38242124__IMC__175_B1,4 | Lung | Primary cancer | 2,713 | Tumor/Malignant | 44.0% | 0.87 | 0.32 |
| NSCLC_38242124__IMC__175_B1,5 | Lung | Primary cancer | 3,623 | Tumor/Malignant | 47.2% | 0.93 | 0.21 |
| NSCLC_38242124__IMC__175_B1,6 | Lung | Primary cancer | 3,146 | Tumor/Malignant | 31.6% | 0.57 | 0.79 |
| NSCLC_38242124__IMC__175_B1,7 | Lung | Primary cancer | 3,665 | Tumor/Malignant | 73.2% | 0.98 | 0.04 |
| NSCLC_38242124__IMC__175_B1,8 | Lung | Primary cancer | 2,860 | Tumor/Malignant | 52.3% | 0.98 | 0.13 |
| NSCLC_38242124__IMC__175_B1,9 | Lung | Primary cancer | 4,697 | Tumor/Malignant | 74.0% | 0.99 | 0.05 |